GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
GALECTIN THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.13 (-3.45%)
Close on Oct 19, 2026
- Market cap
- $230.23M
- P/E (TTM)
- –
- Dividend yield
- –
Galectin Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Market Cap | $352.47M | $166.30M |
| Enterprise Value | $339.20M | $88.19M |
Income (trailing twelve months)
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$15.62M | -$21.40M |
| Net Income | -$27.84M | -$22.46M |
| EBITDA | -$15.62M | -$16.91M |
| EPS (Diluted) | -$0.44 | -$0.83 |
Returns
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -183.0% | -40.9% |
Balance sheet
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $13.27M | $61.43M |
| Net Cash (Debt) | $13.27M | $15.35M |
| Net Cash Per Share | $0.13 | $0.66 |
| Equity (Book Value) | -$138.58M | $49.09M |
| Book Value Per Share | -$1.37 | $1.37 |
| Tangible Book Value | -$138.58M | $23.52M |
| Working Capital | -$136.96M | $76.81M |
Financial position
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.10 | 3.34 |
| Quick Ratio | 0.09 | 2.44 |
| Interest Coverage | -2.02 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$15.89M | -$12.35M |
Efficiency
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.09M | -$703.34K |
| Employee Count | 9 | 74 |
Dividends and yields
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -7.90% | -23.3% |
Shares
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 100,850,000 | 58,127,000 |
| Shares Change (YoY) | 3.55% | 10.9% |
| Shares Change (QoQ) | 0.69% | 0.54% |
| Float | 36,689,400 | 49,136,700 |
| Shares Held by Insiders | 63.6% | 11.6% |
| Shares Held by Institutions | 15.6% | 59.4% |
Scores
| Measure | Galectin Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -55.36 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Galectin Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.